Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Other Non-Current Liabilities (2016 - 2024)

VYNE Therapeutics' Other Non-Current Liabilities history spans 9 years, with the latest figure at $1.3 million for Q1 2024.

  • For Q1 2024, Other Non-Current Liabilities rose 1.0% year-over-year to $1.3 million; the TTM value through Mar 2024 reached $1.3 million, up 1.0%, while the annual FY2023 figure was $1.3 million, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $1.3 million in Q1 2024 per VYNE's latest filing, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.3 million in Q2 2023 to a low of $206000.0 in Q2 2021.
  • Average Other Non-Current Liabilities over 5 years is $639562.5, with a median of $456000.0 recorded in 2020.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 54.82% in 2021, then surged 531.25% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $312000.0 in 2020, then tumbled by 33.97% to $206000.0 in 2021, then rose by 0.97% to $208000.0 in 2022, then soared by 531.25% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024.
  • Per Business Quant, the three most recent readings for VYNE's Other Non-Current Liabilities are $1.3 million (Q1 2024), $1.3 million (Q4 2023), and $1.3 million (Q3 2023).